Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multi-center, Open-label Study of IMGN289 Administered Intravenously in Adult Patients With EGFR-positive Solid Tumors

NCT01963715 is registered in ClinicalTrials.gov with ImmunoGen, Inc. as lead sponsor.

NCT NCT01963715
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01963715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multi-center, Open-label Study of IMGN289 Administered Intravenously in Adult Patients With EGFR-positive Solid Tumors
Lead sponsor
ImmunoGen, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
October 31, 2013
Completion date
April 30, 2015
Enrollment
20 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

egfr positive solid tumors